Business
ImageneBio to Participate in Leerink Global Healthcare Conference
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida. Fireside Date: Tuesday, March 10Time: 3:00pm ESTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company de
About this update from Imagenebio, Inc.
[{"type":"image","alt":"ImageneBio, Inc.","displaySize":"","headline":null,"caption":"ImageneBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":126,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/8676856806afc907243b07503009d2bc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8_3nel2HRyqI7lDiYMAfoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/8676856806afc907243b07503009d2bc","width":126,"height":48}},"lazy":false},{"type":"text","content":"SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida.","length":289,"tagName":"p"},{"type":"text","content":"Fireside Date: Tuesday, March 10Time: 3:00pm ESTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website","length":136,"tagName":"p"},{"type":"text","content":"About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.","length":646,"tagName":"p"},{"type":"text","content":"Investor and Media Contact:[email protected]","length":45,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]